Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs.

Biotechnology

Therapeutics

Thryv Therapeutics

Paul F. Truex

Daphne Doucet

Curtis Mcgrath

Alexandre Brkovic

Marc Vidal

Eric Campeau

Aidan McNeil

Philip Sager

Debra Odink

The Research and Development team at Thryv Therapeutics is dedicated to advancing innovative treatments for genetic disorders related to ventricular repolarization and arrhythmias. This team conducts cutting-edge research, develops new drug candidates, and oversees clinical trials to ensure the safety and efficacy of therapies. Through collaboration among scientists, clinicians, and regulatory experts, they aim to translate complex biological data into actionable therapies that improve patient outcomes.

Research and Development

Corporate Governance

Leadership Team

Research and Development

About

Team members

Other teams at Thryv Therapeutics

Corporate Governance

Leadership Team